Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01077466
Other study ID # NAPMS version 3.4
Secondary ID
Status Completed
Phase Phase 2
First received February 26, 2010
Last updated February 15, 2012
Start date March 2010
Est. completion date January 2012

Study information

Verified date February 2012
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority Denmark: Danish Medicines AgencyDenmark: Ethics CommitteeDenmark: Danish Dataprotection Agency
Study type Interventional

Clinical Trial Summary

The purpose of this study is to study safety and efficacy of natalizumab treatment of primary and secondary progressive multiple sclerosis.

This will be done by measuring the effect of treatment on inflammation in the CNS by means of osteopontin levels in the cerebrospinal fluid (CSF). Safety measures further includes physical and neurological examination,blood samples and MRI measures of disease activity.


Description:

The study will include 12 secondary progressive multiple sclerosis patients and 12 primary progressive multiple sclerosis patients to treatment with IV natalizumab for 60 weeks. At baseline and week 60 a lumbar puncture will be performed. MRI scans will be performed at baseline week 12 and week 60.Safety blood samples will be collected every 12 week.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date January 2012
Est. primary completion date January 2012
Accepts healthy volunteers No
Gender Both
Age group 19 Years to 55 Years
Eligibility Inclusion Criteria:

- Age between 19 and 55 years

- Progressive disease course of multiple sclerosis (primary or secondary)

- Duration of progressive phase of at least 1 year

- Progression of > 1 EDSS point during the last 2 years (>½ EDSS point if EDSS > 5,5)

- EDSS </= 6.5

- Written and informed consent

Exclusion Criteria:

- Pregnancy, breast-feeding or lack of anti.conception for fertile women.

- Attack during the last month before inclusion.

- Treatment with methylprednisolone during 3 months before inclusion.

- Treatment with interferon-beta, glatirameracetate, immunoglobulin G or other immune-modulating treatment 3 months prior to inclusion.

- Treatment with mitoxantrone, cyclophosphamide, azathioprine or other strong immunosuppressive drug 6 months prior to inclusion.

- Prior experimental treatment with strong immunosuppressive drug which the treating physician means will influence the results of the trial.

- Diseases associated with immunodeficiency.

- Treatment with other anticoagulant than aspirin.

- Current malign disease.

- Diabetes Mellitus or other autoimmune disease.

- Renal insufficiency or creatinine > 150 µmol/l.

- Travel in tropical areas 3 months prior to inclusion.

- Acute or chronic infectious diseases, which the treating physician finds relevant (e.g.hepatitis B virus, hepatitis C virus, HIV).

- Psychiatric disease or other circumstances that may limit the patients participation in the trial.

- Contraindication for MRI scan or gadolinium contrast .

- Known hypersensitivity to natalizumab.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Multiple Sclerosis
  • Multiple Sclerosis, Chronic Progressive
  • Primary Progressive Multiple Sclerosis
  • Sclerosis
  • Secondary Progressive Multiple Sclerosis

Intervention

Drug:
Natalizumab
300 mg Natalizumab IV for every 4 week for 56 weeks (15 doses for every patient)

Locations

Country Name City State
Denmark Danish Multiple Sclerosis Center, Section 2082, Rigshospitalet Copenhagen

Sponsors (5)

Lead Sponsor Collaborator
Rigshospitalet, Denmark Biogen, Copenhagen University Hospital, Hvidovre, Signifikans ApS, University of Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cerebrospinal fluid (CSF) osteopontin The primary endpoint is change in CSF osteopontin from baseline to week 60. Change from baseline to week 60 Yes
Secondary Expanded disability status scale (EDSS) Change in expanded disability status scale (EDSS)from baseline to week 60 Baseline to week 60 Yes
Secondary Timed 25-foot Walk (T25FW) Baseline to week 60 Yes
Secondary Multiple Sclerosis Impairment Score (MSIS) Baseline to week 60 Yes
Secondary Multiple Sclerosis Functional Composite Baseline to week 60 Yes
Secondary Short Form 36 Health Survey (SF36) Baseline to week 60 No
Secondary CSF Neurofilament Heavy Chain Change in neurofilament heavy chain in the cerebrospinal fluid Baseline to week 60 Yes
Secondary CSF Myelin Basic Protein Change in myelin basic protein in CSF from baseline to week 60 Baseline to week 60 Yes
Secondary Atrophy Change in normalised brain volume (NBV), grey matter volume (GMV) og white matter volume (WMV) from week 12 to week 60 Week 12 to week 60 Yes
Secondary Magnetization transfer ratio (MTR) Change in MTR in whole brain, lesions, normal-appearing grey matter (NAGM) og normal-appearing white matter (NAWM) from baseline to week 60 Baseline to week 60 Yes
Secondary Diffusion transfer imaging (DTI) Change in FA and ADC in lesions, GM and NAWM between baseline and week 60. Baseline to week 60 Yes
Secondary CSF cell count Change in CSF cell count from baseline to week 60 Baseline to week 60 Yes
Secondary Change in IgG-index Baseline to week 60 No
Secondary CSF nitrogen oxide metabolites Baseline to week 60 No
Secondary CSF-serum albumine concentration quotient Baseline to week 60 No
Secondary CSF CXCL13 Baseline to week 60 Yes
Secondary Matrix metalloproteinase-9 (MMP-9) Baseline to week 60 No
Secondary New Gadolinium-enhancing lesions (GdEL) Baseline to week 60 Yes
Secondary Volume of lesions on T2-weighted MRI images Baseline to week 60 Yes
Secondary Number of new or enlarging lesions on T2-weighted MRI images Baseline to week 60 Yes
See also
  Status Clinical Trial Phase
Completed NCT04239664 - Acceptance Based Telephone Support When Transitioning to SPMS N/A
Active, not recruiting NCT04411641 - Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) Phase 3
Completed NCT02549703 - Mitochondrial Dysfunction and Disease Progression
Terminated NCT01416181 - A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis Phase 3
Withdrawn NCT01181089 - Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS) Phase 1/Phase 2
Active, not recruiting NCT03471338 - Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme N/A
Withdrawn NCT05029609 - Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS Phase 1
Terminated NCT02296346 - Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis N/A
Completed NCT02228213 - Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis Phase 2
Completed NCT00559702 - Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) Phase 1
Terminated NCT03283826 - Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis Phase 1/Phase 2
Completed NCT02253264 - A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients Phase 1
Completed NCT01737372 - A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis N/A
Completed NCT00257855 - A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis Phase 2
Recruiting NCT06292923 - A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients Phase 2
Active, not recruiting NCT01228396 - AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Phase 2
Completed NCT03896217 - Simvastatin in Secondary Progressive Multiple Sclerosis Phase 2
Completed NCT02495766 - Autologous Mesenchymal Stromal Cells for Multiple Sclerosis Phase 1/Phase 2
Completed NCT00813969 - Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS Phase 1
Terminated NCT00146159 - Study Evaluating Mitoxantrone in Multiple Sclerosis Phase 3